<DOC>
	<DOCNO>NCT02647437</DOCNO>
	<brief_summary>Levetiracetam ( LEV : ( S ) -Î±-ethyl-2-oxo-pyrrolidine acetamide ) anticonvulsant/antiepileptic drug . The specific aim study assess efficacy low-dose LEV reduce hippocampal activity schizophrenia . The investigator also hypothesize LEV improve neurocognition patient schizophrenia .</brief_summary>
	<brief_title>Effects Low-dose Levetiracetam Clinical Symptoms , Cognition Hippocampal Hyperactivity Schizophrenia</brief_title>
	<detailed_description>LEV typically administer twice-daily dos 500-1500 mg treatment epilepsy ; dose generally well tolerate ( Patsalos , 2000 ) . Most relevant propose study , LEV ( 125 mg twice-daily , two week administration ) reduce hippocampal hyperactivity improve cognition patient mild cognitive impairment ( MCI ) ( Bakker et al. , 2012 ) . The propose study administer 125 mg immediate release LEV twice-daily two week . This dose choose potentially maximize efficacy minimize side effect . The propose dose substantially low common dose use clinically epilepsy treatment 3000 mg/day .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Diagnosis schizophrenia schizoaffective disorder Good general health Normal vital sign ( blood pressure , pulse , cardiac , pulmonary , abdominal , neurological exam ) Normal renal function ( assess metabolic panel screen result current within three month already available ) 1 . Substance abuse 2 . Significant neurological disorder 3 . Significant head trauma/injury 4 . Lefthandedness 5 . Pregnancy 6 . MRIspecific exclusion criterion ( e.g. , claustrophobia , weight &gt; 450lbs , metal body )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>